How biotechnology research innovator Sano Genetics is accelerating the process of clinical trials in precision medicine.
Finding, screening and engaging patients for clinical trials can be slow and inefficient, particularly in precision medicine. Although accessibility to DNA sequencing has surged in the past decade, precision medicine studies have failed to keep up. They are still complex, time-consuming and costly, and many potentially life-changing treatments never see daylight.
However, Sano Genetics (Sano) is changing this. With a 360° platform that seamlessly connects every stage – strategy consultation, patient finding, biomarker screening, patient engagement and analytics – the biotechnology company’s mission is to accelerate the future of personalised medicine.
Sano was founded in 2017 by Patrick Short, Charlotte Guzzo and William Jones. The three Cambridge PhD students felt there was enormous potential to improve the process of clinical trials – having experienced it as both participants and researchers.
By offering an approach that combines patient recruitment, genetic testing, analytics and long-term patient engagement in one place, Sano is radically improving medical research. The startup is enabling precision medicine teams to move up to 10 times faster, reduce costs by up to 55% and – most importantly – achieve breakthroughs for patients.
Currently, Sano is supporting Neuron23 in its NEULARK Phase 2 clinical trial, a groundbreaking study exploring the brain-penetrant LRRK2 inhibitor NEU-411, which has the potential to slow Parkinson’s progression.
As part of this effort, Sano is providing saliva test kits to identify individuals with LRRK2-driven Parkinson’s disease, offering genetic counseling and facilitating trial referrals to streamline the patient journey.
As the biotechnology startup continues to grow, it has secured flagship partnerships in the US and launched projects aimed at enhancing patient access to clinical trials and advancing precision medicine across the UK.
These initiatives are significantly contributing to the broader healthcare landscape by enabling more inclusive and efficient research which ultimately help to create lifesaving treatments in the near term.
Learn more about Sano Genetics here.
